BioAge Labs Inc.
BIOA
Rank in Stocks
#15308
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops... BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Share Price
$5.87
Last synced: 2026-11-11
Market Cap
$269.50M
Change (1 day)
1.56%
Change (1 year)
-23.96%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade BioAge Labs Inc. (BIOA)
Category
Healthcare
EPS for BioAge Labs Inc. (BIOA)
EPS as of September 2026 TTM: $-2.55
According to BioAge Labs Inc.'s latest financial reports, its current EPS (TTM) is $-2.55. At the end of 2025 the company had an EPS of $-2.24, a decrease compared to its 2024 EPS of $-1.98.
EPS history for BioAge Labs Inc. from 2022 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-2.55 | 13.84% |
| 2025 | $-2.24 | 13.13% |
| 2024 | $-1.98 | 5.88% |
| 2023 | $-1.87 | 61.21% |
| 2022 | $-1.16 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -714.12% |
US
|
|
| $-7.07 | 177.25% |
US
|
|
| $-5.29 | 107.45% |
AU
|
|
| $12.88 | -605.10% |
BE
|
|
| $21.56 | -945.49% |
NL
|
Questions about BioAge Labs Inc.'s earnings per share (EPS)
What is BioAge Labs Inc.'s earnings per share (EPS)?
BioAge Labs Inc.'s earnings per share (EPS) over the last twelve months is $-2.55, as of Sep 2026.
What was BioAge Labs Inc.'s earnings per share (EPS) in 2025?
In 2025, BioAge Labs Inc.'s earnings per share (EPS) was $-2.24, compared with $-1.98 in 2024.
How has BioAge Labs Inc.'s earnings per share (EPS) changed since 2022?
From 2022 to 2025, BioAge Labs Inc.'s earnings per share (EPS) was highest in 2022 ($-1.16) and lowest in 2025 ($-2.24).
How does BioAge Labs Inc.'s earnings per share (EPS) compare with similar companies?
BioAge Labs Inc.'s earnings per share (EPS) ($-2.55) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.